Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Snape

Showing results (61-70 of 169) with videos related to

Pageof 17
Sort By:
The Lancet. Infectious Diseases|November 28, 2017
Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trialDavid Goldblatt, Jo Southern, Nick J Andrews, et al.
Archives of Disease in Childhood|April 1, 2022
National rates and disparities in childhood vaccination and vaccine-preventable disease during the COVID-19 pandemic: English sentinel network retrospective database studyUy Hoang, Simon de Lusignan, Mark Joy, et al.
Archives of Disease in Childhood. Fetal and Neonatal Edition|April 15, 2016
Lymphocyte subpopulations in premature infants: an observational studyAlison Kent, Tim Scorrer, Andrew J Pollard, et al.
Vaccine|April 10, 2013
The B-cell response to a primary and booster course of MenACWY-CRM₁₉₇ vaccine administered at 2, 4 and 12 months of ageGeraldine Blanchard-Rohner, Matthew D Snape, Dominic F Kelly, et al.
The Pediatric Infectious Disease Journal|August 21, 2013
Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trialMatthew D Snape, John Philip, Tessa M John, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 6, 2008
The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster responseGeraldine Blanchard Rohner, Matthew D Snape, Dominic F Kelly, et al.
Cell Reports|June 13, 2019
Common Genetic Variations Associated with the Persistence of Immunity following Childhood ImmunizationDaniel O'Connor, Eileen Png, Chiea Chuen Khor, et al.
Pediatrics|May 13, 2024
Safety and Immunogenicity of an mRNA-Based hMPV/PIV3 Combination Vaccine in Seropositive ChildrenSabine Schnyder Ghamloush, Brandon Essink, Bo Hu, et al.
The Journal of Infectious Diseases|December 11, 2019
Antibody-Dependent Natural Killer Cell Activation After Ebola VaccinationHelen R Wagstaffe, Elizabeth A Clutterbuck, Viki Bockstal, et al.
The Pediatric Infectious Disease Journal|September 17, 2010
Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trialMatthew D Snape, Tom Dawson, Philipp Oster, et al.
Pageof 17

Showing results (61-70 of 169) with videos related to

Sort By:
Pageof 17
The Lancet. Infectious Diseases|November 28, 2017
Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trialDavid Goldblatt, Jo Southern, Nick J Andrews, et al.
Archives of Disease in Childhood|April 1, 2022
National rates and disparities in childhood vaccination and vaccine-preventable disease during the COVID-19 pandemic: English sentinel network retrospective database studyUy Hoang, Simon de Lusignan, Mark Joy, et al.
Archives of Disease in Childhood. Fetal and Neonatal Edition|April 15, 2016
Lymphocyte subpopulations in premature infants: an observational studyAlison Kent, Tim Scorrer, Andrew J Pollard, et al.
Vaccine|April 10, 2013
The B-cell response to a primary and booster course of MenACWY-CRM₁₉₇ vaccine administered at 2, 4 and 12 months of ageGeraldine Blanchard-Rohner, Matthew D Snape, Dominic F Kelly, et al.
The Pediatric Infectious Disease Journal|August 21, 2013
Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trialMatthew D Snape, John Philip, Tessa M John, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 6, 2008
The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster responseGeraldine Blanchard Rohner, Matthew D Snape, Dominic F Kelly, et al.
Cell Reports|June 13, 2019
Common Genetic Variations Associated with the Persistence of Immunity following Childhood ImmunizationDaniel O'Connor, Eileen Png, Chiea Chuen Khor, et al.
Pediatrics|May 13, 2024
Safety and Immunogenicity of an mRNA-Based hMPV/PIV3 Combination Vaccine in Seropositive ChildrenSabine Schnyder Ghamloush, Brandon Essink, Bo Hu, et al.
The Journal of Infectious Diseases|December 11, 2019
Antibody-Dependent Natural Killer Cell Activation After Ebola VaccinationHelen R Wagstaffe, Elizabeth A Clutterbuck, Viki Bockstal, et al.
The Pediatric Infectious Disease Journal|September 17, 2010
Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trialMatthew D Snape, Tom Dawson, Philipp Oster, et al.
Pageof 17